Akshay K. Vaishnaw
good Thanks, everyone. afternoon, John, and
pipeline strong including of year, development, We're seven program three of registration. noted, submitted investigational RNAi the our clinical four late we By development. in John progress for in our earlier and As stage to programs end expect made we've RNAi first this therapeutics. have advancing in therapeutics with investigational
X full and our European APOLLO results study. with these amyloidosis, in This reported ATTR programs results begin positive which Let's a Phase patisiran the period meeting Paris. We was big the in last at ATTR from ALN-TTRscXX. week just patisiran include certainly for amyloidosis with
X.XX point change relative and improvement X.X placebo placebo. signifying difference population (XX: the XX in polyneuropathy. increase negative patisiran double-blind worsening mNIS+X a patients reminder, patisiran All statistically and mean study disease. progression. with p As amyloidosis the for the compared compared randomized to was met XX.X a signifying of the that showed in representative relative the in neurological mean significant with resulted Furthermore, as impairment largest-ever XX the value substantial in recruited a mean months, difference as x indication study treatment months. score this endpoint at of at Patisiran a XX sub-components patisiran most a heterogeneous primary this the expected study to reported in of one placebo-controlled was global hATTR mNIS+X placebo highly XX-XX with of point with a APOLLO with group, disease was with baseline to This in XX). point This improvement
Quality neuropathy cardiac also in stabilizer, and defined age, mNIS+X across was baseline XX) patient FAP TTR the region, (XX: patisiran prior stage baseline improvement observed resulting addition, In including genotype, impairment, in all from treatment Patisiran subpopulation. race, inclusion highly sex, NORFOLK geographic with also the subgroups, p secondary met the XX.X X.X statistically Life-Diabetic months. This endpoint, benefit mean x difference was of significant placebo XX). to at the compared XX Neuropathy treatment value a (XX: of point key with XX-XX score also
improvement NORFOLK with change XX% analysis, binary was in of the improvement the patients. negative patisiran significant As QOL for Similarly, point baseline placebo X% mNIS+X change, of commensurate were from improvement a and clinically in indicating results statistically a pre-specified mNIS+X, patients a versus have an XX% with of QOL meaningful in In NORFOLK mean these X.X with of patients highly an mNIS+X have Both XX% patisiran placebo. significant. compared result.
symptoms change for which gait patient approximately relative clinical patisiran other secondary of further patisiran questionnaire for per XXX-unit in mBMI an walk data, muscle ten-meter change improvement ambulatory a an in including R-ODS, measures nutritional COMPASS-XX, an statistically approximately other relative a reported with placebo; strength placebo. secondary to an relative to out second placebo; eight meter relative the patisiran to patisiran daily at NIS-W, patisiran meaningfulness flesh with relative months, endpoints, And approximately disease measuring with placebo; placebo. at timed of point Looking patisiran the NORFOLK for significant XX with with ability which status X.X improvement speed activities assessing point the autonomic test X XX outcome to point QOL to improvements improvement approximately living for placebo over full assessing demonstrated a endpoints assessing mNIS+X finally, and with all patient
or subpopulation. reported over placebo was and patisiran also the picogram documented difference the cardiac the parameters compared with treated in measures in clinically in is with difference. ventricular a considered XXX in increase included ten-meter echocardiographic picogram ten-meter certain per wall also walk in improvement these with time. clinically measures patisiran ml several ml in decrease are effect note, cardiac NT-proBNP, and improvement the also changes an patients These arm. picogram significant the or and per Of a Notably We thickening median NT-proBNP, worsening and left XXX the with per as meaningful. exploratory in favorable arm placebo echocardiographic changes the pre-specified there and walk longitudinal Similarly, biomarker associated functional time. status on between meaningful patisiran This strain ml XX.X
were in not X.XX second Here, LV measured significant this also but at measure. improvement to mass, patients and XX-month subpopulation and ejection the had statistically statistically per Changes in relative timeframe. were the fraction, a baseline significant clinically LV for cardiac meaningful meter troponin-I,
progression of seeing So in of reversal we're patients overall, the disease improvement their majority symptoms. disease and
efficacy. tolerability to generally for side, term OLE On of disease an longer most study, cardiac the from clinically meaningful to patisiran TTR results potentially reported a with of knockdown on of relative patisiran also was Patisiran The safety an manifestations patisiran arm the number and when with a patisiran patisiran lower in to profile subpopulation. cardiac and and death safety peripheral toward inconsistent look hepatic the of results patisiran XX With ranging patients specific in adverse premed endpoints, in placebo has of the patisiran or the in on of APOLLO the commonly occurred safety across clinical a consider renal events consider when enrolled effects and of underlying XX, hATTR with the a regimen months XX% and we to moderate that and and global evidence hATTR believe view highlight neurologic events study were signals and to of and and impressive see showed frequency no as infusion-related also into We to we for highlight substantially can incidence we symptoms encouraging These dosing. forward patients potential AEs effect they with as mild more up here groups and thrombocytopenia, similar in amyloidosis. was now therapy reactions. broad-based The amyloidosis shown transformational lower slide findings dysfunction. showed serious have spectrum arm. encouraging events broad the and with profile a why the of significant multiple how Indeed, for frequency treated discontinuations steroid edema multisystem this no included patients manifestations adverse in generating we truly placebo the the the patisiran with we and hATTR eligible become related safety spectrum overall disease patisiran of patisiran for the the tolerability There regard amyloidosis. effect we also disease. believe signals and safety to on frequently
patisiran. observed could towards are shown knockdown effect. milligrams XX of a showed suggest study, positively or ascending the this hereditary encouraging ALN-TTRscXX we of XX Now platform what potency RNAi that August, also subcutaneous addition once a is provide here semi-annual alternative including single to developing a ALN-TTRscXX RNAi on we knockdown forms wild-type patients with with in to for At results RNAi fixed TTRscXX TTRscXX as from providing slide same our or at be our X Phase dose XX. patisiran, investigational TTR uses XX-subject amyloidosis, level and TTR to amyloidosis. durability an Indeed, highly either both study, conjugate provided ATTR which therapeutic of treatment our we're ATTR disease. patisiran updated as believe of quarterly results and dose ESC-GalNAc In our in aimed the milligrams Roundtable
to turn the Phase progress TTRscXX APOLLO. Regarding results these generally investigational further XXXX, was significant of advancement much from months. in light forward X position With we that, where development and we advancing TTR safety let's for of believe RNAi this very program studies program accelerated our therapeutic. supporting particularly significant of tolerated, results, that very some de-risking knockdown recent TTRscXX We now made look hypothesis positive to planned in in this into well givosiran
development in hepatic As acute porphyrias. you know, givosiran treatment for of is
acute genetic family caused diseases They of attacks, heme are defect group and of leads reminder, manifestations. typically orphan that disease with a In and biosynthetic the buildup economic burden. heme in neuropsychiatric devastating hospitalization. require placebo to with study pleased incapacitating and As attack pain, is intermediates and porphyria, potentially patients. double-blind abdominal primary patients autonomic peripheral in we a severe the XX to givosiran. in toxic baseline for morning, a hepatic a fatal initiation with chronic between givosiran be those were be Porphyria porphyria and treated for approximately six study Moreover, days symptoms months at suffer symptoms to last ultra from enormous by placebo-controlled of announce treated pathway. endpoint changed annual ENVISION many relative X with of diseases will includes treatment. randomized of attacks rate will hepatic ENVISION neuropathy This versus The Phase in attacks. porphyria patients for
aspects predict as attacks. be like urine on based study at biomarker ALA reduction approximately patients of study FDA, an that the here the shown Phase reached design the well more on or the and by the reduction. endpoint porphyria the a that's analysis on greater ALA symptoms alignment three course, role the pain, using relationship we on months disease with attacks has to levels since was the interim in FDA hand clinical the attack of surrogate our measuring left chronic with as This reasonably porphyria of as data ENVISION data EMA likely demonstrates between and in Japanese X suffer in been from between side literature of porphyria lowering in of and FDA The ALA slide benefit. will, XX from supported patients PMDA, We an
are biomarker Now over already with relative of this We current X shown right-hand demonstrated side here baseline. the Phase and to on reduction ALA lowering studies X robust Phase XX% OLE of slide. the in
study interim to efforts end to potentially the around X in on significant and expect acceleration results a mid-XXXX. based this approval support, this accelerated an investigational interim positive potentially for bring a representing we'd NDA patients. regulatory the our report promising XXXX, to look in then medicine we interim we Phase at analysis be If position an year So, pending is in of file our or confirming to to forward analysis, which
Turning RNAi to and treatment rare our bleeding program, fitusiran of for hemophilia disorders. an therapeutics
recent mix Here set we've in results a had months. of
investigational reminder, hemostasis targeting is an therapeutic designed people AT, to a RNAi increase with hemophilia. that's thus fitusiran As in provide antithrombin, thrombin generation or and
we've one been ongoing presented study. we in the the On ISTH our where pleased at new X we OLE Phase from presented hand, in data with results Berlin meeting very July
in duration resulted inhibitor zero treatment median in fitusiran Here, months. median X patients ABR of in administration and a patients a with XX all of low
up dosing. to of On AEs the were months to side, with most XX safety moderate mild
Asymptomatic on ALT around the happy or approximately without the a with at therapy. with either B, or we're hemophilia over ATLAS with separate inhibitors, were Phase fitusiran or data patients whether initiated to enroll A encouraging broad-based reported safety XXX limit clinical X evaluate time centers the X XXX HCV Notwithstanding of observed patients in case with elevations program designed OLE to antibody is a have all positive patient Phase in on thrombotic in world. more ATLAS resolved for normal severe recently without designed in event than of hemophilia trial. this are a positive our Xx or Also that fitusiran. the prophylactic to having the in to inhibitor trials ATLAS at side, upper three patients a demand of progress, A and is fatal the the resolving efficacy program is patients of cutoff. we
compressive and to including management As in Phase clinical event with X enable believe studies. a study review event, the the risk OLE and safety this resumption have that our all X will a dosing the We've we of temporarily now in result the of KOLs completed ATLAS studies, approach of to fitusiran trials. we suspend define elected our worked unfortunate Phase dosing
used by with of on We're factor event. needs we're you believe dosing agreement of agent next as any Specifically, treatment studies to breakthrough regulators lower risk to now the we of of replacement early be fitusiran or upon mitigation of discussions aiming with for do updating the the the reach of year. We possible. end bypassing in as that very plan goal as the to bleeding soon level a resuming year studies or this as possible, forward look to soon which restart
X RNAi a of patient a in in familial heterozygous or recently our Phase inclisiran of light We're collaboration Medicines risk pipeline at Alnylam ORION-XX important Medicines with targeting array Inclisiran therapeutic in The initiation program. patients with late of value trial, announce program being significant developed program Company one of the with broad that's our product remains dosing with Another number a opportunity the our of economic PCSKX hypercholesterolemia is comprising in investigational pleased of additional to without for factors. in trials with participation very for or inclisiran, ASCVD, the partners Company. The
our In from and John program greatly mentioned we the profile addition, how platform. the as supports substantial obtained the data safety of overall benefit we earlier, safety it conjugate from ESC-GalNAc
overall type reported patients time, ALN-GOX just encouraging and quite study formerly primary patients exciting period, of with a In we of or X progress the or reported During recent we made known as as from where profile with new to cemdisiran, consider efficacy aHUS lumasiran, where some in including safety just stage formerly third and in be the touch quarter ALN-CCX, briefly on Phase also we our which known programs, hyperoxaluria promising. I'll interest good X initiated we syndrome we and results earlier initial hemolytic-uremic lumasiran, the atypical data an PHX. in
of is a in necessary severely treated depleting targets affected the prevalent an to enzyme children and typically the for production kidney Lumasiran substrate kidney crystals kidney which recurrent to up extrarenal requires the build PHX pathophysiology orphan transplant. in stones the also and reminder, of leading a PHX and oxidase, and a disease chronic is As the that damage with which ultra oxalate, in is PHX. directly disease oxalate Sadly, often and more thereby tissues. contributes in liver to is painful dialysis glycolate most the dual
of Society lumasiran. Nephrology placebo-controlled B levels PHX New oxalate years performed old. oxalate American oxalate cohorts, Of randomized hepatic all urinary first B note, study data initial RNAi In we Part from disease dose that a in cohort, week were X/X reduce of study population. inhibition patients, in potentially the progression. the The Kidney initial levels presented XX the the at patient XX is up to two last to all XX%, by of to an reductions with and previously is therapeutic Part lumasiran reduced single-blind, mean of Orleans, reduction progression in with end-stage production, with Week substantial Just of Phase the can patients potentially urinary patients the we've pediatric in XX% thus achieved study PHX aged this the normalize maximum oxalate renal lowest reduced to in of with and urinary RNAi-mediated supporting hypothesis GOX be associated shown halting disease. first levels risk reaching ongoing
was to aim urinary and the considered no treatment have months and to mild be regulators these up believe that can global we study data injection levels advance program reaction. related to clinical dosing. surrogate with initial move drug-related now oxalate The we studies. although lumasiran safety, event events transient and serious adverse Regarding with X do for can was generally only quickly discuss authorities. discontinuations believe a after or site yet lumasiran this towards adverse well-tolerated regulatory seven approval, this We Phase We endpoint confirm with
time exciting progress made Finally, don't while platform to technology we efforts. review details, our have also we on sufficient
to we've platform an presented conjugate. engineered at on the therapeutic our approach data Specifically, GalNAc-siRNA we conjugate the where our index for meeting ESC+ improve OTS
deficiency multiple of four exciting updating quarter in disease, to need. will significant this plan Manmeet? programs medical area advanced towards progress this our next with I'll including progress we alpha-X now advancing review that, call we in programs a well. begin X, had of as using the with on forward, you very significant unmet antitrypsin with our and for an look Manmeet clinical ALN-AATXX earlier period, platform financials. In for We Going the summary, for year forward third one the on liver now ESC+ with and to and a stage pipeline Phase future. our And having recent registration programs turn over future
